BTG3 and autoimmune disease: The authors agreed that autoantibodies, ANA and other organ-specific or non-organ-specific autoantibodies should be detected in patients with NMOSD to identify systemic or organ-specific autoimmune diseases and to help predict the prognosis of patients with NMOSD.